Agomab Therapeutics announced positive Phase 1 results for AGMB-447, a candidate for idiopathic pulmonary fibrosis (IPF). The data show a generally favorable safety and tolerability profile, efficient lung restriction with low systemic exposure, and no new specific or systemic safety signals at any dose. No increase in disease-related cough severity was reported. The company intends to initiate a Phase 2 trial before year-end. This is an early-stage biotech (market cap $643M) with a first/primary commercial asset, so a positive Phase 1 readout is directionally bullish, though Phase 1 data are preliminary and do not establish efficacy. The primary endpoint for the planned Phase 2 is change from baseline in forced vital capacity at Week 24. Note: the filing contains no financial figures.
Price Chart
Executive Summary
Agomab Therapeutics announced positive Phase 1 results for AGMB-447, a candidate for idiopathic pulmonary fibrosis (IPF). The data show a generally favorable safety and tolerability profile, efficient lung restriction with low systemic exposure, and no new specific or systemic safety signals at any dose. No increase in disease-related cough severity was reported. The company intends to initiate a Phase 2 trial before year-end. This is an early-stage biotech (market cap $643M) with a first/primary commercial asset, so a positive Phase 1 readout is directionally bullish, though Phase 1 data are preliminary and do not establish efficacy. The primary endpoint for the planned Phase 2 is change from baseline in forced vital capacity at Week 24. Note: the filing contains no financial figures.
Financial Impact
Not specified
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3361543 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | Insider Buy | $9.26 | awaiting T+5 | — | $9.11 (−1.62%) |
Oct 13, 2026 12d ago | 6-K | $8.69 $9.11 | ▲ +4.83% | ▲ +4.38% | $9.11 (+4.83%) |
Oct 13, 2026 12d ago | Press Release | $8.69 $9.11 | ▲ +4.83% | ▲ +4.38% | $9.11 (+4.83%) |
Oct 1, 2026 25d ago | 6-K | $8.65 $9.22 | ▲ +6.59% | ▲ +5.29% | $9.11 (+5.32%) |
Oct 1, 2026 25d ago | Press Release | $8.65 $9.22 | ▲ +6.59% | ▲ +5.29% | $9.11 (+5.32%) |
Sep 14, 2026 5w ago | 6-K | $12.16 $11.49 | ▼ −5.51% | ▼ −7.64% | $9.11 (−25.08%) |
Sep 14, 2026 5w ago | Press Release | $12.16 $11.49 | ▼ −5.51% | ▼ −7.64% | $9.11 (−25.08%) |
Sep 11, 2026 6w ago | 6-K | $12.28 $11.70 | ▼ −4.72% | ▼ −4.83% | $9.11 (−25.81%) |
Aug 10, 2026 10w ago | 6-K | $14.85 $13.73 | ▼ −7.54% | ▼ −7.14% | $9.11 (−38.65%) |
Jun 23, 2026 17w ago | 6-K | $12.68 $11.87 | ▼ −6.39% | ▼ −8.10% | $9.11 (−28.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers